Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis.
Arteriosclerosis
Cardiovascular events
Hemodialysis
Klotho
Mortality
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
11 06 2019
11 06 2019
Historique:
received:
19
02
2019
accepted:
17
05
2019
entrez:
13
6
2019
pubmed:
13
6
2019
medline:
29
9
2020
Statut:
epublish
Résumé
Klotho is a transmembrane protein acting as a co-receptor for FGF-23 and thus exerts clinical actions on mineral metabolism. The association of secreted Klotho with outcomes in CKD patients is unclear. This study examined the relation between plasma Klotho and cardiovascular events in dialysis patients, accounting for common and CKD-MBD related risk factors, arterial stiffness and atherosclerotic burden. Seventy-nine chronic hemodialysis patients were observed for a median follow-up of 5.5 years. Klotho levels as well as carotid-femoral pulse wave velocity (cfPWV) and common carotid intima-media thickness (ccIMT) measurements were performed at baseline. The primary end-point was first occurrence of all-cause death, non-fatal myocardial infarction or non-fatal stroke. Secondary end-points were: (i) all-cause mortality; (ii) cardiovascular mortality; (iii) a combination of cardiovascular death, non-fatal MI, non-fatal stroke, resuscitation after cardiac arrest, coronary revascularization, heart failure hospitalization and atrial fibrillation. Cumulative freedom from the primary endpoint was 31% for the low-Klotho group (≤745 pg/ml) and 53% for the high-Klotho group (logrank p = 0.017); HR: 2.137, 95%CI 1.124-4.065. Cumulative survival was insignificantly lower (44% vs 56%, p = 0.107), but cumulative cardiovascular survival (63% vs 88%, p = 0.029) and cumulative freedom from the cardiovascular composite outcome (18% vs 45%, p = 0.009) were significantly lower in the low-Klotho group. In modelled Cox-regression analysis the association of low Klotho with the primary endpoint remained significant after stepwise adjustment for cFGF3, PTH, Ca x P product, established risk factors (age, dialysis vintage, diabetes, hypertension, smoking, history of cardiovascular disease) as well as cfPWV and ccIMT [Model 6: HR:2.759, 95%CI 1.223-6.224, p = 0.014]. Low Klotho is associated with cardiovascular events in hemodialysis patients, independently from factors associated with mineral-bone disease, common risk factors and intermediate outcomes, such as cfPWV and ccIMT.
Sections du résumé
BACKGROUND
Klotho is a transmembrane protein acting as a co-receptor for FGF-23 and thus exerts clinical actions on mineral metabolism. The association of secreted Klotho with outcomes in CKD patients is unclear. This study examined the relation between plasma Klotho and cardiovascular events in dialysis patients, accounting for common and CKD-MBD related risk factors, arterial stiffness and atherosclerotic burden.
METHODS
Seventy-nine chronic hemodialysis patients were observed for a median follow-up of 5.5 years. Klotho levels as well as carotid-femoral pulse wave velocity (cfPWV) and common carotid intima-media thickness (ccIMT) measurements were performed at baseline. The primary end-point was first occurrence of all-cause death, non-fatal myocardial infarction or non-fatal stroke. Secondary end-points were: (i) all-cause mortality; (ii) cardiovascular mortality; (iii) a combination of cardiovascular death, non-fatal MI, non-fatal stroke, resuscitation after cardiac arrest, coronary revascularization, heart failure hospitalization and atrial fibrillation.
RESULTS
Cumulative freedom from the primary endpoint was 31% for the low-Klotho group (≤745 pg/ml) and 53% for the high-Klotho group (logrank p = 0.017); HR: 2.137, 95%CI 1.124-4.065. Cumulative survival was insignificantly lower (44% vs 56%, p = 0.107), but cumulative cardiovascular survival (63% vs 88%, p = 0.029) and cumulative freedom from the cardiovascular composite outcome (18% vs 45%, p = 0.009) were significantly lower in the low-Klotho group. In modelled Cox-regression analysis the association of low Klotho with the primary endpoint remained significant after stepwise adjustment for cFGF3, PTH, Ca x P product, established risk factors (age, dialysis vintage, diabetes, hypertension, smoking, history of cardiovascular disease) as well as cfPWV and ccIMT [Model 6: HR:2.759, 95%CI 1.223-6.224, p = 0.014].
CONCLUSIONS
Low Klotho is associated with cardiovascular events in hemodialysis patients, independently from factors associated with mineral-bone disease, common risk factors and intermediate outcomes, such as cfPWV and ccIMT.
Identifiants
pubmed: 31185930
doi: 10.1186/s12882-019-1391-1
pii: 10.1186/s12882-019-1391-1
pmc: PMC6560885
doi:
Substances chimiques
FGF23 protein, human
0
Fibroblast Growth Factor-23
7Q7P4S7RRE
Glucuronidase
EC 3.2.1.31
Klotho Proteins
EC 3.2.1.31
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
217Références
Biochem Biophys Res Commun. 2004 Feb 6;314(2):409-14
pubmed: 14733920
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
Science. 2005 Sep 16;309(5742):1829-33
pubmed: 16123266
N Engl J Med. 2008 Aug 7;359(6):584-92
pubmed: 18687639
Endocrine. 2009 Jun;35(3):341-6
pubmed: 19367378
Circulation. 2009 May 19;119(19):2545-52
pubmed: 19414634
Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19308-13
pubmed: 20966350
J Gerontol A Biol Sci Med Sci. 2011 Jul;66(7):794-800
pubmed: 21474560
J Am Soc Nephrol. 2011 Oct;22(10):1913-22
pubmed: 21903574
J Clin Invest. 2011 Nov;121(11):4393-408
pubmed: 21985788
Kidney Int. 2012 Apr;81(7):640-50
pubmed: 22237753
Kidney Int. 2013 Jan;83(1):121-8
pubmed: 22895520
Nephrol Dial Transplant. 2013 Feb;28(2):352-9
pubmed: 23129826
Nephrol Dial Transplant. 2013 Jan;28(1):153-61
pubmed: 23180879
Nat Commun. 2012;3:1238
pubmed: 23212367
PLoS One. 2013;8(2):e56695
pubmed: 23431388
Am J Kidney Dis. 2013 Jun;61(6):899-909
pubmed: 23540260
BMC Nephrol. 2013 Jun 12;14:122
pubmed: 23758931
Curr Vasc Pharmacol. 2015;13(2):229-38
pubmed: 24007427
Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1049-58
pubmed: 24677555
PLoS One. 2014 Apr 02;9(4):e93423
pubmed: 24695641
J Am Heart Assoc. 2014 Jun 10;3(3):e000936
pubmed: 24922628
PLoS One. 2014 Jul 03;9(7):e100688
pubmed: 24991914
Am J Nephrol. 2014;40(3):242-50
pubmed: 25322847
J Am Soc Nephrol. 2015 May;26(5):1150-60
pubmed: 25475745
Am J Kidney Dis. 2015 Aug;66(2):258-65
pubmed: 25804679
Am J Nephrol. 2015;41(4-5):400-8
pubmed: 26139107
Atherosclerosis. 2015 Oct;242(2):483-9
pubmed: 26298739
Int J Endocrinol. 2015;2015:406269
pubmed: 26604925
Am J Kidney Dis. 2016 Mar;67(3 Suppl 1):Svii, S1-305
pubmed: 26925525
Kidney Int. 2017 May;91(5):1104-1114
pubmed: 28131398
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3154-3161
pubmed: 28402487
Hypertension. 2017 Jul;70(1):148-157
pubmed: 28483919
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017 Sep 1;38(2):19-27
pubmed: 28991773
Iran J Public Health. 2018 Apr;47(4):510-518
pubmed: 29900135
Atherosclerosis. 2018 Sep;276:83-90
pubmed: 30048945
Kidney Int. 1997 Jun;51(6):1678-95
pubmed: 9186855
Nature. 1997 Nov 6;390(6655):45-51
pubmed: 9363890